Vaccine provides protection against herpes

Trial vaccine protects against herpes infection, according to a study published in the New England Journal of Medicine.The results show only a partial success, but researchers have described as significant progress in creating a vaccine against herpes.

Herpes is a viral disease. Once emerged passes into the latent phase and finds clinical expression in different periods of time throughout life.

Apply medication that alleviates the current status of events, but can not achieve a complete cure.

The disease is caused by herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).

HSV-2 causes lesions and blisters on the genitals, while HSV-1 usually leads to the formation of sores in the mouth.

Infection with herpes can cause severe neurological diseases and even fatal in infants, whether they are infected during childbirth or from contact with the sick in the first months.

Trial vaccine provides partial protection against herpes simplex virus type 1 shows the study. It includes more than 8,000 women aged 18 to 32 years in the U.S. and Canada. Funded by a World Health Organization and Institute of Allergy and Infectious Diseases NIAID.

Scientists from the University of St. Louis, Missouri, reported 58 percent fewer cases of infection with HSV-1 in women who were vaccinated, compared with those who are not immunized.

The results show that two of the three doses of the vaccine offers protection against skin manifestations caused by herpes simplex virus type 1.

The vaccine does not protect against herpes simplex virus type 2.

Scientists say the reason may be due to the fact that HSV-1 is more vulnerable to antibodies from HSV-2.